Histone deacetylase and tubulin deacetylase inhibitors
US8304451B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 2, 2007 |
| Grant date | Nov 6, 2012 |
| Priority date | — |
| Expiry date | Jul 14, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel inhibitors of histone deacetylases, tubulin deacetylases, and/or aggresome inhibitors, and pharmaceutically acceptable salts and derivatives thereof. The inventive compounds fall into two classes—“isotubacin” class and “isoisotubacin” class—all of which include a 1,3-dioxane core. The present invention further provides methods for treating disorders regulated by histone deacetylase activity, tubulin deacetylase activity, and/or the aggresome (e.g., proliferative diseases, cancer, inflammatory diseases, protozoal infections, protein degradation disorders, protein deposition disorders, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. The present invention also provides methods for preparing compounds of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.